High tumour contamination of leukaphereses in patients with small cell carcinoma of the lung: a comparison of immunocytochemistry and RT-PCR.
In small-cell lung carcinoma (SCLC) tumour cell contamination of leukaphereses is unknown. The present study was performed to define appropriate markers for reverse transcriptase polymerase chain reaction (RT-PCR), then to assess the contamination rate of leukaphereses and corresponding bone marrow samples. Immunocytochemistry (ICC) and RT-PCR methods were also compared. Among the 33 patients included, analyses were performed in 16 who had multiple leukaphereses and 17 who had only bone marrow. Leukapheresis products and bone marrow were analysed by ICC using several specific monoclonal antibodies against neural-cell adhesion molecule (N-CAM), epithelial glycoprotein (EGP-40) and cytokeratins (CK). Samples were also analyzed by RT-PCR for expression for N-CAM, synaptophysin, neuron-specific enolase, chromogranin, cytokeratin-18/-19, CEA, EGP-40, apomucin type 1 (MUC-1) and human endothelial cell-specific molecule (ESM-1). Using ICC staining, contaminating tumour cells were detected in 34% of leukaphereses (27% in patients with limited disease and 43% in those with extensive disease). N-CAM was the most reliable marker for detection of contamination. For RT-PCR, CK-19 and CEA were the only appropriate markers. Positive signal rate in leukaphereses increased to 78% (89% for patients with limited disease and 67% for extensive disease). In bone marrow, both techniques were in agreement whereas in leukaphereses, RT-PCR was better than ICC. A high rate of tumour cell contamination was demonstrated not only in bone marrow but also in leukaphereses from SCLC patients. The most appropriate technique was RT-PCR mainly in patients with limited disease.
Perey
L
L
Centre Pluridisciplinaire d'Oncologie and the Institut de Pathologie, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland.
Benhattar
J
J
Peters
R
R
Jaunin
P
P
Leyvraz
S
S
D000328:Adult; D000368:Aged; D000951:Antigens, Neoplasm / Q000032:analysis / Q000235:genetics; D001853:Bone Marrow / Q000737:chemistry / Q000473:pathology; D002272:Carcinoembryonic Antigen / Q000032:analysis / Q000235:genetics; D018288:Carcinoma, Small Cell / Q000097:blood / Q000628:therapy*; D015815:Cell Adhesion Molecules / Q000032:analysis / Q000235:genetics; D002864:Chromogranins / Q000032:analysis / Q000235:genetics; D000071858:Epithelial Cell Adhesion Molecule; D005260:Female; D005752:Gastric Mucins / Q000032:analysis / Q000235:genetics; D006801:Humans; D007150:Immunohistochemistry; D007633:Keratins / Q000032:analysis / Q000235:genetics; D007937:Leukapheresis; D008175:Lung Neoplasms / Q000097:blood / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D009363:Neoplasm Proteins; D009360:Neoplastic Cells, Circulating / Q000378:metabolism / Q000473:pathology*; D019006:Neural Cell Adhesion Molecules / Q000032:analysis / Q000235:genetics; D010751:Phosphopyruvate Hydratase / Q000032:analysis / Q000235:genetics; D011506:Proteins / Q000032:analysis / Q000235:genetics; D011509:Proteoglycans; D012334:RNA, Neoplasm / Q000235:genetics / Q000378:metabolism; D020133:Reverse Transcriptase Polymerase Chain Reaction; D016708:Synaptophysin / Q000032:analysis / Q000235:genetics
D000951:Antigens, Neoplasm; D002272:Carcinoembryonic Antigen; D015815:Cell Adhesion Molecules; D002864:Chromogranins; C101134:ESM1 protein, human; D000071858:Epithelial Cell Adhesion Molecule; D005752:Gastric Mucins; D009363:Neoplasm Proteins; D019006:Neural Cell Adhesion Molecules; D011506:Proteins; D011509:Proteoglycans; D012334:RNA, Neoplasm; D016708:Synaptophysin; C053366:apomucin; D007633:Keratins; D010751:Phosphopyruvate Hydratase